The Pharmalliance Days A Brief History of Pharmalliance
The Lucas Building, Adelaide University Research Park, Thebarton Campus
Pharmalliance Pty Ltd was founded in July, 1996 to market the Twenty-first Century HealthCare Products that had been – and were continuing to be – created by its founder, Dr Warwick D Raymont, a reserach scientist.
Initially Pharmalliance was operated from Dr Raymont’s Greenwith South Australia home but, within several months, had begun to outgrow the home and, in July 1997, moved into Commercial premises in Norwood, on the Eastern fringe of Adelaide's Central Business District ("CBD").
By the end of 2002, the Pharmalliance turnover had increased to the extent that much larger premises again had become needed. At that time, the University of Adelaide invited Dr Raymont to move Pharmalliance to a large building that had become available at its Thebarton Research Campus, on the Western fringe of the Adelaide CBD. Pharmalliance now had six Complementary Medicine and Nutritional Products on the market, four of which were based on the Patents that Dr Raymont had been awarded.
In early 2003 Mrs Welke, Dr Raymont’s business partner, sold her share in the Company to See Hang Chong of Hong Kong and the Company accepted the University's invitation and moved its operations to Adelaide University Research Park, Thebarton Campus. The business, its turnover and its profitability continued increasing exponentially.
Within weeks of the move, Australia's Therapeutic Goods Administration (TGA) closed Pan Pharmaceuticals, the manufacturer responsible for over 70% of Australian Contract Pharmaceutical manufacturing. Pan Pharmaceuticals had been manufacturing two of the three major selling Pharmalliance Products, Emmugen and Mennugen. As luck would have it, they were running behind in the delivery of the next batch of each, which really worked out in Pharmalliance's favour, because, had they been on time, Pharmalliance would have had to recall the entire batch of both products. As it was, as a result of Pan Pharmaceuticals' collapse, Pharmalliance had lossesassessed at $389,000 on these two batches alone.
It was to be nearly two years before these two products, Emmugen and Mennugen, could be re-manufactured due to the stringency with which the TGA was now enforcing manufacturing regulations as a result of the closure of Pan Pharmaceuticals and the fact that the few remaining manufacturers were inundated with Pan's former customers.
In late 2004, a third shareholdercame into Pharmalliance, Mrs Constanze Voelkel-Hutchison, a Senior Executive of DIMEA (The Commonwealth Department of Immigration, Multiculturalism and Ethnic Affairs). Her cash injection helped Pharmalliance through the issues caused by Pan Pharmaceuticals.
By April,2005, all products were back on the market. In June, 2005, the Company recorded its greatest yet month of sales and sales were growing enormously, especially in the Retail Market - Pharmacies and Clinics. The projected before-tax profit of the Company for the financial, year ended June 30, 2006 had been professionally assessed at over $500,000 and it was clear that the Pan Pharmaceuticals losses would soon be overcome.
However, in late 2005, Pharmalliance was subjected to a hostile takeover that immediately saw Dr Raymont forced out as a Director and Officer of the Company. The action of the new majority shareholders and the management they appointed took the Company down a path that ultimately led to the business failing, causing immense cost and damage to its founder, Dr Raymont who, regrettably, had absolutely no control over their actions.
Today, in the absence of any assistance from investors (despite numerous unfulfilled promises), he is taking his former Pharmalliance Products into the future by himself, re-introducing them one by one as sales and profits allow. "Softly, softly, catchee monkey" is the business principle he has adopted.The commercial vehicle he is using to market hisproducts is "Southern Synergy", a wholly owned subsiduary of Stolair.
In the beginning of 2017, he re-introduced his fibre product, now named "AusFibre", and, as soon as sufficient funds have accumulated, plans to re-introduce his long-awaited OxiChel. This, along with all his former Pharmalliance's products, has been fine-tuned to embrace the latest discoveries and developments in human health and nutrition before being re-introduced to the Australian Market. As market penetration re-occurs in Australia, export markets, particularly the Asia-Pacific market, will be gradualy entered.
Watch the "Southern Synergy" website (www.southernsynergy.com.au) for the latest news and progress!
The Foyer at Thebarton Campus
Thabarton Campus Gateway
Thebarton Campus Boardroom
Pharmalliance Personal Care Products enriched with Ducane Kunzea ambigua oil